This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-small cell lung cancer (NSCLC); bone cancer	Ubiquitin specific peptidase 1 (USP1); WD repeat domain 48 (WDR48; UAF1)	Cell-based studies suggest inhibiting the USP1-UAF1 complex could help increase NSCLC and bone cancer sensitivity to platinum-based chemotherapies. In a cisplatin-resistant NSCLC cell line, a USP1-UAF1 inhibitor combined with cisplatin decreased cell proliferation compared with either of the agents alone or vehicle control. In a human osteosarcoma cell line, the inhibitor plus cisplatin decreased proliferation compared with cisplatin alone. Next steps include testing the inhibitor in mouse models of cancer.	Patent filed by the NIH and University of Delaware; available for licensing	Liang, Q. <i>et al. Nat. Chem. Biol.</i> ; published online Feb. 16, 2014; doi:10.1038/nchembio.1455 Contact: Zhihao Zhuang, University of Delaware, Newark, Del. e-mail: zzhuang@udel.edu Contact: David J. Maloney, National Institutes of Health, Bethesda, Md. e-mail: maloneyd@mail.nih.gov
		SciBX 7(14); doi:10.1038/scibx.2014.398 Published online April 10, 2014		